मूलभूत आँकड़े
| CIK | 1435181 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pharmagreen Biotech Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-56090 PHARMAGREEN BIOTECH INC. (Exact name of registrant as specified in |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 (Commission File Number) PHARMAGREEN BIOTECH INC. ( |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 (Commission File Number) PHARMAGREEN BIOTECH INC. |
|
| May 18, 2023 |
EXHIBIT 16.2 May 16, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Ladies and Gentlemen, We have read the statements of Pharmagreen Biotech Inc. relating to the event described under Item 4.01 of Form 8-K dated April 27, 2023, and we agree with such statements as they pertain to our firm. Respectfully, Sadler, Gibb & Associates, LLC Draper, UT S|G Phone: 80 |
|
| May 18, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2023 Pharmagreen Biotech, Inc. (Exact name of registrant as specified in its charter) 000-56090 92-1737808 (Commission File Number) (IRS Employer Identification Number) 2987 Black |
|
| May 18, 2023 |
Letter from Sadler, Gibb & Associates, LLC to the Company dated April 27, 2023 EXHIBIT 16.1 April 27, 2023 Pharmagreen Biotech Inc. 2987 Blackbear Court Coquitlam, British Columbia Canada, V3E3A2 Effective April 27, 2023, Sadler, Gibb & Associates, LLC (“the Firwill cease providing services as and terminates its role as your Independent Registered Public Accounting Firm. We have reached this decision because Pharmagreen Biotech Inc. no longer meets the Firm’s risk profile. F |
|
| May 12, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 (Commission File Number) PHARMAGREEN BIOTECH IN |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTECH INC. (Exact |
|
| December 28, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended September 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N- |
|
| December 2, 2022 |
EXHIBIT 99.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of November 2, 2022, by and between PHARMAGREEN BIOTECH INC, a Nevada corporation, with its address at 2987 Blackbear Court, Coquitlam, British Columbia, CANADA (the ?Company?), and JANBELLA GROUP, LLC., a North Carolina limited liability company, with its address at 20013 Chartwell Ctr. Dr. S |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 000-56090 98-0491567 (State or other jurisdiction of incorporation) (Commissio |
|
| December 2, 2022 |
THE ISSUE PRICE OF THIS NOTE IS $50,000.00 EXHIBIT 99.2 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTECH INC. (Ex |
|
| August 12, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR F |
|
| August 11, 2022 |
EXHIBIT 16.1 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 U.S.A. Dear Ladies and Gentlemen: Re: Pharmagreen Biotech Inc. (the ?Company?) This letter confirms that we have reviewed Item 4.01, Changes in Registrant?s Certifying Accountant, of the Company?s Form 8-K dated August 10, 2022 and are in agreement with the statements made therein as it pertains to our firm. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 333-151350 26-1679929 (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTECH INC. (E |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTECH INC. |
|
| February 14, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-S |
|
| December 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTECH INC. |
|
| October 4, 2021 |
Pharmagreen Biotech Inc. 300,000,000 Shares of Common Stock Filed Pursuant to Rule 253(g)(2) File No. 024-11505 OFFERING CIRCULAR Pharmagreen Biotech Inc. 300,000,000 Shares of Common Stock By this Offering Circular, Pharmagreen Biotech Inc., a Nevada corporation, is offering for sale a maximum of 300,000,000 shares of its common stock (the ?Offered Shares?), at a fixed price of $0.025 per share, pursuant to Tier 2 of Regulation A of the United States Secu |
|
| September 23, 2021 |
PHARMAGREEN BIOTECH INC. 2987 Blackbear Court Coquitlam, British Columbia Canada V3E 3A2 CORRESP 1 filename1.htm PHARMAGREEN BIOTECH INC. 2987 Blackbear Court Coquitlam, British Columbia Canada V3E 3A2 September 23, 2021 VIA EDGAR Karina Dorin Staff Attorney Office of Energy & Transportation Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Pharmagreen Biotech Inc. (the “Company”) Offering Statement on Form 1-A (the “Offer |
|
| August 30, 2021 |
As filed with the Securities and Exchange Commission on August 30, 2021 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated August 30, 2021 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the SEC). |
|
| August 30, 2021 |
CONSENT OF INDEPENDENT REGISTERED EXHIBIT 11.1 |
|
| August 24, 2021 |
Services Agreement between Registrant and FlinnWest Solutions. EXHIBIT 10.2 |
|
| August 24, 2021 |
Production and Broadcast Agreement between Registrant and New to the Street Group LLC. EXHIBIT 10.1 |
|
| August 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2021 Pharmagreen Biotech, Inc. (Exact name of registrant as specified in its charter) Nevada 000-56090 26-1679929 (State or other jurisdiction of incorporation) (Commission File |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTECH INC. (Ex |
|
| August 16, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended June 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR F |
|
| July 16, 2021 |
NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road – Suite 107-762 Flower Mound, Texas 75022 July 16, 2021 CORRESP 1 filename1.htm NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road – Suite 107-762 Flower Mound, Texas 75022 940-367-6154 July 16, 2021 Karina Dorin Staff Attorney Office of Energy & Transportation Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Pharmagreen Biotech Inc. Amendment No. 1 to Offering Statement on Form 1-A Filed June 2 |
|
| July 16, 2021 |
As filed with the Securities and Exchange Commission on July 16, 2021 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated July 16, 2021 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the SEC). |
|
| June 23, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2021 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 333-151350 26-1679929 (State or other jurisdiction of incorporation) (Commission F |
|
| June 23, 2021 | ||
| June 22, 2021 |
SUBSCRIPTION AGREEMENT Pharmagreen Biotech Inc. NOTICE TO INVESTORS SUBSCRIPTION AGREEMENT Pharmagreen Biotech Inc. NOTICE TO INVESTORS The securities of Pharmagreen Biotech Inc., a Nevada corporation (the “Company”), to which this Subscription Agreement relates, represent an investment that involves a high degree of risk, suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investments. |
|
| June 22, 2021 |
As filed with the Securities and Exchange Commission on June , 2021 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated June , 2021 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the SEC). |
|
| June 22, 2021 | ||
| June 22, 2021 |
NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road – Suite 107-762 Flower Mound, Texas 75022 NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road – Suite 107-762 Flower Mound, Texas 75022 940-367-6154 June 10, 2021 Karina Dorin Staff Attorney Office of Energy & Transportation Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| June 22, 2021 | ||
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTECH |
|
| June 9, 2021 |
NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road, Suite 107-762 Flower Mound, Texas 75022 June 8, 2021 NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road, Suite 107-762 Flower Mound, Texas 75022 940-367-6154 June 8, 2021 Mr. |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTECH INC |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 333-151350 26-1679929 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One:) ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR Fo |
|
| April 14, 2021 |
EX1A-6 MAT CTRCT 27 ex616.htm |
|
| April 14, 2021 |
EX1A-12 OPN CNSL 43 ex121.htm NEWLAN & NEWLAN, LTD. 2201 Long Prairie Road – Suite 107-762 Flower Mound, Texas 75022 940-367-6154 April 8, 2021 Pharmagreen Biotech Inc. 2987 Blackbear Court Coquitlam, British Columbia Canada V3E 3A2 Re:Offering Statement on Form 1-A Gentlemen: We have been requested by Pharmagreen Biotech Inc., a Nevada corporation (the “Company”), to furnish you with our opinion |
|
| April 14, 2021 |
EX1A-6 MAT CTRCT 14 ex615.htm |
|
| April 14, 2021 |
As filed with the Securities and Exchange Commission on April , 2021 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated April , 2021 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the SEC). |
|
| April 14, 2021 |
SUBSCRIPTION AGREEMENT Pharmagreen Biotech Inc. NOTICE TO INVESTORS The securities of Pharmagreen Biotech Inc., a Nevada corporation (the ?Company?), to which this Subscription Agreement relates, represent an investment that involves a high degree of risk, suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investments. |
|
| April 14, 2021 |
Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors of Pharmagreen Biotech Inc. (the “Company”) We hereby consent to the use, in this Offering Statement on Form 1-A of our Report of Independent Registered Public Accounting Firm dated January 7, 2021 relating to the consolidated financial statements of the Company as at and for the years ended September 3 |
|
| April 14, 2021 |
EX1A-2A CHARTER 8 ex27.htm |
|
| April 14, 2021 |
EX1A-2A CHARTER 4 ex26.htm |
|
| April 14, 2021 |
EX1A-6 MAT CTRCT 41 ex631.htm Broker-Dealer Agreement This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between Pharmagreen Biotech, Inc (“Client”), a Nevada Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of March 29, 2021 (the “Effe |
|
| March 22, 2021 | ||
| March 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2021 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 333-151350 26-1679929 (State or other jurisdiction of incorporation) (Commission |
|
| March 22, 2021 | ||
| March 3, 2021 |
- PHARMAGREEN BIOTECH - REQUEST FOR WITHDRAWAL OF FORM S-1 PHARMAGREEN BIOTECH INC. 112 North Curry Street, Carson City, Nevada 89703 March 3, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporate and Finance 100 F Street NE Washington, DC 20549-7010 Re:Pharmagreen Biotech Inc. (the ?Company?) Request to Withdraw Registration Statement on Form S-1 (RW) SEC File Number 333-238126 Dear Sirs: Pursuant to Rule 477(a) promulgated under the Se |
|
| February 23, 2021 |
Quarterly Report - FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTEC |
|
| February 22, 2021 |
Quarterly Report - FORM 10-Q FOR THREE MONTHS ENDED DECEMBER 31, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTECH |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One:) ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2020 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR |
|
| January 8, 2021 |
Annual Report - FORM 10-K FOR YEAR ENDED SEPTEMBER 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREEN BIOTECH I |
|
| December 29, 2020 |
Form 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One:) x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2020 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report |
|
| October 28, 2020 |
Schedule 14C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement PHARMAGREEN BIOTECH INC. (Name of Registran |
|
| October 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2020 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 333-151350 26-1679929 (State or other jurisdiction of incorporation) (Commissio |
|
| October 16, 2020 |
Material Modification to Rights of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2020 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 333-151350 26-1679929 (State or other jurisdiction of incorporation) (Commissio |
|
| October 16, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement PHARMAGREEN BIOTECH INC. (Name of Registrant as Specifie |
|
| August 19, 2020 |
PBI Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGREE |
|
| August 12, 2020 |
PHARMAGREEN BIOTECH AIMS TO RESTRUCTURE DEBT, PROTECT THE COMPANY AND ITS SHAREHOLDERS PHARMAGREEN BIOTECH AIMS TO RESTRUCTURE DEBT, PROTECT THE COMPANY AND ITS SHAREHOLDERS CARSON CITY, NV, August 11, 2020 Pharmagreen Biotech, Inc. |
|
| August 12, 2020 |
Form 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One:) ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2020 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Fo |
|
| August 12, 2020 |
Regulation FD Disclosure, Bankruptcy or Receivership - SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August , 2020 PHARMAGREEN BIOTECH INC. (Exact name of registrant as specified in its charter) Nevada 333-151350 26-1679929 (State or other jurisdiction (Commission File Number) (IRS Employer of Inc |
|
| July 21, 2020 |
Pharmagreen Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 21, 2020 |
Consulting Agreement |
|
| June 23, 2020 |
- DEFINITIVE INFORMATION STATEMENT Schedule 14C - Definitive SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement PHARMAGREEN BIOTECH INC. (Name |
|
| June 12, 2020 |
- PRELIMINARY INFORMATION STATEMENT Schedule 14C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement PHARMAGREEN BIOTECH INC. (Name of Registran |
|
| May 22, 2020 |
ex99-1 |
|
| May 22, 2020 |
Converted by Wiklow Corporate Services Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2020 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 333-151350 26-1679929 (State or other j |
|
| May 19, 2020 |
Quarterly Report - FORM 10-1 FOR SIX MONTHS ENDED MARCH 31, 2020 PBI Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMAGRE |
|
| May 13, 2020 |
Form 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One:) ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2020 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on F |
|
| May 8, 2020 |
Registration Statement - FORM S-1 REGISTRATION STATEMENT Pharmagreen S-1 April 28, 2020 (W0394141).DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 3590 98-0491567 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Nu |
|
| March 4, 2020 |
Exhibit 99.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 23, 2020, is entered into by and between Pharmagreen Biotech, Inc., a Nevada corporation (the “Company”), and BHP Capital NY, Inc., a New York corporation (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of |
|
| March 4, 2020 |
PHARMAGREEN BIOTECH INC. 8% CONVERTIBLE REDEEMABLE NOTE DUE JANUARY 21, 2021 Exhibit 99.6 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $66,15 |
|
| March 4, 2020 |
Pharmagreen Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 4, 2020 |
Exhibit 99.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| March 4, 2020 |
PHARMAGREEN BIOTECH INC. 10% CONVERTIBLE REDEEMABLE NOTE DUE JANUARY 22, 2021 Exhibit 99.8 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $78,75 |
|
| March 4, 2020 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 14, 2020, by and between PHARMAGREEN BIOTECH INC., a Nevada corporation, with headquarters located at 2987 Blackbear Court, Coquitlam, British Columbia, Canada, V3E 3A2 (the “Company”), and CROWN BRIDGE PARTNERS, LLC, a New York limited liability company, with its address at 1173a 2 |
|
| March 4, 2020 |
Exhibit 99.11 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| March 4, 2020 |
Exhibit 99.7 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 22, 2020, by and between Pharmagreen Biotech Inc, a Nevada corporation, with headquarters located at 2987 Blackbear Court, Coquitlam, BC V3E 3A2, Canada (the “Company”), and LG CAPITAL FUNDING LLC, a New York limited liability company, with its address at 1218 Union Street, Suite #2 |
|
| March 4, 2020 |
Exhibit 99.9 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 23, 2020 , by and between PHARMAGREEN BIOTECH INC., a Florida corporation, with headquarters located at 2987 Blackbear Court, Coquitlam, BC V3E 3A2, Canada (the “Company”), and GS CAPITAL PARTNERS, LLC a New York limited liability company, with its address at 30 Washington Street, S |
|
| March 4, 2020 |
Exhibit 99.5 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 21, 2020 , by and between PHARMAGREEN BIOTECH INC., a Florida corporation, with headquarters located at 2987 Blackbear Court, Coquitlam, BC V3E 3A2, Canada (the “Company”), and ADAR ALEF, LLC a New York limited liability company, with its address at 38 Olympia Lane, Monsey, NY 10952 |
|
| March 4, 2020 |
PHARMAGREEN BIOTECH INC. 10% CONVERTIBLE REDEEMABLE NOTE DUE JANUARY 23, 2021 Exhibit 99.10 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE 1933 ACT) US $61,0 |
|
| March 4, 2020 |
Exhibit 99.2 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| February 18, 2020 |
PBI Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 or [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission File Number PHARMA |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One:) ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2019 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR |
|
| January 24, 2020 |
Pharmagreen 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2020 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 333-151350 26-1679929 (State or other jurisdiction of incorporat |
|
| December 30, 2019 |
PBI Form 10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K [ X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-56090 Commission file num |
|
| December 2, 2019 |
Promissory Note issued to Oscaleta Partners LLC Exhibit 10.3 |
|
| December 2, 2019 |
Exhibit 10.2 |
|
| December 2, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Pharmagreen equity line 8-K disclosure (W0386801).DOCX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2019 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 333-151350 26-1679929 (S |
|
| December 2, 2019 |
Exhibit 10.1 |
|
| November 8, 2019 |
Securities Purchase Agreement dated October 17, 2019 with Power Up Lending Group Ltd. Exhibit 10.5 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 17, 2019, by and between Pharmagreen Biotech Inc., a Nevada corporation, with its address at 2987 Blackbear Court, Coquitlam, British Columbia V4E 3A2 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Great |
|
| November 8, 2019 |
Securities Purchase Agreement dated October 1, 2019 with EMA Financial, LLC. Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of October 1, 2019, is entered into by and between Pharmagreen Biotech Inc., a Nevada corporation (the “Company”), and EMA Financial, LLC, a Delaware limited liability company (the “Purchaser” or “Holder”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant |
|
| November 8, 2019 |
Convertible Promissory Note dated October 1, 2019 with EMA Financial, LLC. Exhibit 10.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| November 8, 2019 |
Convertible Promissory Note dated October 17, 2019 with Power Up Lending Group Ltd Exhibit 10.6 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,AS AMENDED,OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE,SOLD,TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECU |
|
| November 8, 2019 |
Financial Statements and Exhibits Pharmagreen - Form 8-K Power Up SPA September 19, 2019 (W0385153).DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 19, 2019 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 333-1513 |
|
| November 8, 2019 |
Securities Purchase Agreement dated September 17, 2019 with Power Up Lending Group Ltd. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 17, 2019, by and between Pharmagreen Biotech Inc., a Nevada corporation, with its address at 2987 Blackbear Court, Coquitlam, British Columbia V4E 3A2 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Grea |
|
| November 8, 2019 |
Convertible Promissory Note dated September 17, 2019 with Power Up Lending Group Ltd NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,AS AMENDED,OR APPLICABLE STATE SECURITIES LAWS. |
|
| September 11, 2019 |
Financial Statements and Exhibits Pharmagreen - Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 11, 2019 |
Agreement dated September 3, 2019 with Emerging Markets Consulting, LLC Exhibit 10.1 |
|
| September 6, 2019 |
Pharmagreen Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 5, 2019 |
PHBI / Pharmagreen Biotech Inc. 8-A12G - - FORM 8-A12G Pharmagreen Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 19, 2019 |
Pharmagreen Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 14, 2019 |
AITG / Air Transport Group Holdings, Inc. NT 10-Q - - NOTIFICATION OF LATE FILING Form 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response .... 2.50 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2019 [ ] Transition Repo |
|
| July 9, 2019 |
AITG / Air Transport Group Holdings, Inc. CORRESP - - Request for Accelerated Effectiveness July 9, 2019 Ronald Alper Division of Corporation Finance Office of Transportation and Leisure Securities and Exchange Commission Re: Pharmagreen Biotech Inc. |
|
| June 24, 2019 |
Pharmagreen Form S-1, Amendment No. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 A4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Pharmagreen Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 3590 98-0491567 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) |
|
| June 24, 2019 |
Date: June 21, 2019 Ronald Alper Division of Corporation Finance Office of Transportation and Leisure Securities and Exchange Commission Re: Pharmagreen Biotech Inc. |
|
| June 11, 2019 |
Pharmagreen Form S-1, Amend #3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 11, 2019 |
SEC Response Letter Date: June 11, 2019 Ronald Alper Division of Corporation Finance Office of Transportation and Leisure Securities and Exchange Commission Re: Pharmagreen Biotech Inc. |
|
| June 5, 2019 |
Date: June 4, 2019 Ronald Alper Division of Corporation Finance Office of Transportation and Leisure Securities and Exchange Commission Re: Pharmagreen Biotech Inc. |
|
| June 5, 2019 |
Pharmagreen Form S-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 10, 2019 |
Date: May 9, 2019 Ronald Alper Division of Corporation Finance Office of Transportation and Leisure Securities and Exchange Commission Re: Pharmagreen Biotech Inc. |
|
| May 10, 2019 |
Pharmagreen Form S-1, Amend 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 20, 2019 |
Exhibit 2.5 |
|
| March 20, 2019 |
Exhibit 3.2 |
|
| March 20, 2019 |
Exhibit 3.3 |
|
| March 20, 2019 |
Exhibit 2.6 |
|
| March 20, 2019 |
AITG / Air Transport Group Holdings, Inc. REGISTRATION STATEMENT Pharmagreen Form S-1 As filed with the Securities and Exchange Commission on March 20, 2019 Registration No. |
|
| March 20, 2019 |
Exhibit 2.1 |
|
| March 20, 2019 |
Exhibit 2.3 |
|
| March 20, 2019 |
Exhibit 2.9 |
|
| March 20, 2019 |
Exhibit 2.2 |
|
| March 20, 2019 |
Exhibit 2.8 |
|
| March 20, 2019 |
Exhibit 2.4 |
|
| March 20, 2019 |
Exhibit 2.7 |
